AI Article Synopsis

  • The study examined the effects of single doses of propranolol, practolol, and metoprolol on heart rate during submaximal exercise in normal volunteers.
  • Exercise increased heart rates significantly, and different beta-blockers showed varying effectiveness in reducing exercise-induced tachycardia.
  • Metoprolol, with its cardioselective properties, proved to be the most effective at reducing heart rates, making it preferable to practolol in treatment.

Article Abstract

1. The effects of single oral doses of propranolol, practolol and a new cardioselective beta-adrenoceptor blocking drug, metoprolol, on exercise-induced tachycardia in relation to plasma levels were studied in six normal volunteers. 2. Exercise undertaken on treadmill was submaximal which, under control conditions, increased the heart rate from 74-3 (s.e.m. = 6-8) to 153-8 (s.e.m. = 9.8) beats/min. 3. Plasma concentrations of propranolol and practolol were assayed fluorometrically and of metoprolol by electron-capture gas liquid chromatography, the details of which are described. 4. Between 1-5 and 2 h after drug ingestion 80 mg of propranolol associated with plasma level of 50-60 ng/ml (half-life 2-75 h), reduced the exercise-induced tachycardia by 27%, 250 mg of practolol with plasma levels of 1050-1100 ng/ml reduced it by 28% and 100 mg of metoprolol with plasma concentrations of 140-150 ng/ml (half-life 1-7 h), reduced it by 30%. 5. The resting heart rates were reduced significantly by propranolol and metoprolol but not by practolol. 6. Metoprolol is a potent short-acting beta-adrenoceptor antagonist; its advantages as a cardioselective agent over practolol in therapeutic use are discussed.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1440-1681.1976.tb00625.xDOI Listing

Publication Analysis

Top Keywords

propranolol practolol
12
exercise-induced tachycardia
12
plasma levels
12
practolol metoprolol
8
metoprolol exercise-induced
8
tachycardia relation
8
relation plasma
8
plasma concentrations
8
ng/ml half-life
8
practolol
6

Similar Publications

Background: β-adrenergic antagonists (BAAs) are used to treat cardiovascular disease such as ischemic heart disease, congestive heart failure, dysrhythmias, and hypertension. Poisoning from BAAs can lead to severe morbidity and mortality. We aimed to determine the utility of extracorporeal treatments (ECTRs) in BAAs poisoning.

View Article and Find Full Text PDF

Beta-adrenergic blocking agents (abbreviated as beta-blockers) have been used for treating various cardiovascular diseases. However, the potential for asthma exacerbation is one of the major adverse effects of beta-blockers. This study aimed to compare the level of risk for an asthma attack in patients receiving various beta-blockers.

View Article and Find Full Text PDF

Drug absorption in celiac disease.

Am J Health Syst Pharm

December 2013

Tran H. Tran, Pharm.D., BCPS, is Assistant Clinical Professor, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, and Clinical Pharmacy Manager, New York Presbyterian Hospital/Columbia Medical Center, New York. Candace Smith, Pharm.D., is Associate Clinical Professor and Chair, Clinical Pharmacy Practice Department; and Robert A. Mangione, Ed.D., B.S.Pharm., is Provost and Professor of Pharmacy, College of Pharmacy and Health Sciences, St. John's University.

Purpose: Published evidence on established and theorized effects of celiac disease on drug absorption and pharmacokinetics is reviewed.

Summary: Patients with celiac disease develop a variety of gastric disorders requiring oral medications, but the impact of damage to intestinal villi and other celiac disease sequelae on drug absorption remains poorly understood. A review of the pertinent literature (English-language articles on research in adults published during the period 1970-August 2012) identified several reports of altered drug absorption mechanisms in patients with celiac disease, including accelerated or delayed gastric emptying, increased permeability of jejunal mucosa, changes in intraluminal pH, decreased intestinal surface area, and reduced intestinal cytochrome P-450 enzymes.

View Article and Find Full Text PDF

Sixteen beta-adrenergic antagonists namely acebutalol, alprenolol, atenolol, bisoprolol, bopindolol, bufurolol, carazolol, celiprolol, indenolol, metaprolol, nebivolol, oxprenolol, practolol, propranolol, tertalol, and timolol, and two beta-adrenergic agonists namely cimeterol and clenbuterol were resolved on AmyCoat (150 x 46 mm, 3 microm size of silica particle) by using (85:15:0.1, v/v/v), (90:10:0.1, v/v/v), and (95:05:0.

View Article and Find Full Text PDF

Hydrophobicity-aided potentiometric detection of catecholamines, beta-agonists, and beta-blockers in a mixed-solvent capillary electrophoresis system.

J Sep Sci

January 2009

Instituto de Quimica Fisica de Materiales, Ambiente y Energia (INQUIMAE), Departamento de Quimica Inorganica, Analytica y Quimica Fisica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina.

A series of cationic drug-like substances with distinct basicity, hydrogen-bonding ability, and hydrophobicity, including three catecholamines, two beta-agonists, and thirteen beta-blockers, was successfully detected in a capillary electrophoresis system using an end-capillary coupled potentiometric sensor consisting of a PVC-based liquid membrane deposited directly on a 100 mum diameter copper rod. The electrophoretic separation was performed on a 72 cm x 75 microm id uncoated fused-silica capillary with an acidic background electrolyte containing phosphoric acid in a water-acetonitrile mixture, pH* 2.8.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!